Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Goodwill (2021 - 2024)

Zentalis Pharmaceuticals has reported Goodwill over the past 4 years, most recently at $3.7 million for Q3 2024.

  • For Q3 2024, Goodwill changed 0.0% year-over-year to $3.7 million; the TTM value through Sep 2024 reached $3.7 million, changed 0.0%, while the annual FY2023 figure was $3.7 million, 0.0% changed from the prior year.
  • Goodwill for Q3 2024 was $3.7 million at Zentalis Pharmaceuticals, roughly flat from $3.7 million in the prior quarter.
  • Over five years, Goodwill peaked at $3.7 million in Q4 2021 and troughed at $3.7 million in Q4 2021.
  • A 4-year average of $3.7 million and a median of $3.7 million in 2021 define the central range for Goodwill.
  • On a YoY basis, Goodwill climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
  • Year by year, Goodwill stood at $3.7 million in 2021, then changed by 0.0% to $3.7 million in 2022, then changed by 0.0% to $3.7 million in 2023, then changed by 0.0% to $3.7 million in 2024.
  • Business Quant data shows Goodwill for ZNTL at $3.7 million in Q3 2024, $3.7 million in Q2 2024, and $3.7 million in Q1 2024.